Journal Of Pharmaceutical Sciences
CRM197, a single amino acid mutant of diphtheria toxoid, is a commonly used carrier protein in commercial polysaccharide-protein conjugate vaccines. In this study, CRM197proteins from three different expression systems and five different manufacturers were obtained for an analytical comparability assessment using a wide variety of physicochemical and in vitro antigenic binding assays. A comprehensive analysis of the five CRM197molecules demonstrate that recombinant CRM197's expressed in heterologous systems (E. coli and Pseudomonas fluorescens) are overall highly similar (if not better in some cases) to those expressed in the traditional system (Corynebacterium diphtheriae) in terms of primary sequence/post translational modifications, higher-order structural integrity, apparent solubility, physical stability profile (vs. pH and temperature) and in vitro antigenicity. These results are an encouraging step to demonstrate that recombinant CRM197expressed in alternative sources have the potential to replace CRM197expressed in C. diphtheriae as a source of immunogenic carrier protein for lower-cost polysaccharide conjugate vaccines. The physicochemical assays established in this work to monitor the key structural attributes of CRM197should also prove useful as complementary characterization methods (to routine quality control assays) to support future process and formulation development of lower-cost CRM197carrier proteins for use in various conjugate vaccines. Copyright 2018. Published by Elsevier Inc.